Projects per year
Nanomedicine, Antibodies, Antibody-Drug Conjugates (ADCs), cathepsin proteases, cancer, inflammation, infection
Professor Chris Scott is Director of the Patrick G Johnston Centre for Cancer Research. Following a primary degree in Biochemistry he undertook a PhD and post doctoral training at Queen’s in molecular enzymology. In 2001, Chris was one of the founding members of QUB spinout company Fusion Antibodies Ltd., before returning to Queen’s in 2003 to take up an academic position. Chris is internationally renowned for his work in development of antibody and nanomedicine-based therapies for the treatment of cancer and other conditions. Work in his laboratory is funded by agencies such as Medical Research Council, US-Ireland, and various industrial sources such as AstraZeneca and Immunocore. He also held a Royal Society Industrial Fellowship with GSK from 2012-15, and won the Vice Chancellor’s Prize for Innovation in 2015 with his group’s work on developing a novel nanomedicine for the treatment of sepsis and other inflammatory conditions. Chris is a member of the Medical Research Council Developmental Pathway Funding Scheme Panel.
Expertise related to UN Sustainable Devlopment Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
- 1 Similar Profiles
Dive into details
Select a country/territory to view shared publications and projects
10/01/2020 → …
R1846CNR: Development of intracellular VNARs as novel tools to dissect intracellular biological processes
20/12/2017 → …
Boland, A. J., O'Kane, A. A., Buick, R., Longley, D. B. & Scott, C. J., Aug 2021, In: Biochimica et Biophysica Acta - Reviews on Cancer. 1876, 1, 20 p., 188557.
Research output: Contribution to journal › Article › peer-review
Suleiman, H., Taggart, C., Scott, C. & Williams, R., 25 Feb 2021, Winter School (Medicine, Dentistry and Biomedical Sciences) Meeting 2021: Proteinases and their Inhibitors.
Research output: Chapter in Book/Report/Conference proceeding › Conference contribution
Development of an Inhaled CatS Inhibitor for the Treatment of CF: *This talk won the best talk of the session prizeFleming, C., Scott, C., Taggart, C. & Williams, R., 24 Feb 2021.
Research output: Contribution to conference › Paper › peer-review
Enhanced target-specific delivery of docetaxel-loaded nanoparticles using engineered T cell receptorsMcDaid, W. J., Lissin, N., Pollheimer, E., Greene, M., Leach, A., Smyth, P., Bossi, G., Longley, D., Cole, D. K. & Scott, C. J., 20 Aug 2021, (Early online date) In: Nanoscale.
Research output: Contribution to journal › Article › peer-reviewOpen AccessFile8 Downloads (Pure)
Anti-DLL4 VNAR targeted nanoparticles for targeting of both tumour and tumour associated vasculatureLeach, A., Smyth, P., Ferguson, L., Steven, J., Greene, M. K., Branco, C. M., McCann, A. P., Porter, A., Barelle, C. J. & Scott, C. J., 21 Jul 2020, In: Nanoscale. 12, 27, p. 14751-14763 13 p.
Research output: Contribution to journal › Article › peer-reviewOpen AccessFile